DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Radotinib is an investigational drug.
There have been 6 clinical trials for Radotinib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 14th 2018.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Ulsan University Hospital, and Asan Medical Center.
There is one US patent protecting this investigational drug and eighteen international patents.
Recent Clinical Trials for Radotinib
|Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE)||Il-Yang Pharm. Co., Ltd.||Phase 3|
|A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Resistance/Intolerance to Previous TKIs||Il-Yang Pharm. Co., Ltd.||Phase 3|
|Radotinib as 3rd or Later Line Therapy in CP-CML||Ulsan University Hospital||Phase 2|
Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Radotinib||Start Trial||N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof||Il-Yang Pharm. Co., Ltd. (Gyeonggi-do, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|